Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.45 |
| ▸ | ABL1 | P00519 | 2/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | LTK | P29376 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12095668 | 0.75 | LMNA (0.53) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL2642265 | 0.74 | GCK (0.62) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL8976752 | 0.69 | EGFR (0.78) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL4745458 | 0.69 | ADORA3 (0.65) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL31004010 | 0.69 | ADORA3 (0.65) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| Acrylamide SCHEMBL4278962 | 0.66 | EGFR (0.70) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL6831353 | 0.66 | EGFR (0.62) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL4751092 | 0.66 | ADORA3 (0.56) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL29236749 | 0.65 | ABCG2 (0.62) | ABCG2ABL1DAPK3MAP4K4EGFR | |
| SCHEMBL27960202 | 0.64 | ABCG2 (0.48) | ABCG2ABL1DAPK3MAP4K4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2019832-B1 | PROCESS FOR THE PREPARATION OF PYRAZOLYLAMINOQUINAZOLINE DERIVATIVES COMPRISING A PHOSPHATE GROUP | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | CDK19, CDK16, AURKC | ABCG2 1406/4885ABL1 145/4885DAPK3 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.